JDD Buzz Series | The Burden of Melasma
A study in the August Journal of Drugs in Dermatology addressed the burden of melasma – the populations most prone to melasma and the comorbidities associated with it. According to the study’s authors, a deeper understanding of the associations of race, ethnicity and comorbidities can help dermatologists determine which patients are at risk of developing melasma and as well as potential new pa …
A study in the August Journal of Drugs in Dermatology addressed the burden of melasma – the populations most prone to melasma and the comorbidities associated with it. According to the study’s authors, a deeper understanding of the associations of race, ethnicity and comorbidities can help dermatologists determine which patients are at risk of developing melasma and as well as potential new pa … 
A 68-year-old man presents for a full-body skin examination 2 days after undergoing Mohs micrographic surgery for a squamous cell carcinoma of the left helix. The patient has a second appointment with the Mohs surgeon in 20 days. However, the patient is extremely frustrated with the appearance of his ear and wants alternative therapies for his ear. Which of the following is the most appropriat … 
TikTok is a source of beauty and skin health information for the masses. Yet much of the content is not produced by board-certified dermatologists or even other healthcare professionals. So who’s creating TikTok content about sun protection and skin cancer? Does any of this content address skin of color? Those are the questions a new cross-sectional analysis published in the July Journal of Drug … 
Health recently asked if it’s ever OK to go outside without sunscreen. The article highlighted the American Academy of Dermatology’s approach of always wearing sunscreen when going outside as well as recent discussion in the U.S. and Australia that questions the strict guidance, especially in light of vitamin D.
For an expert’s take, I reached out to Heather Woolery-Lloyd, MD, director of … 
Cemiplimab is a monoclonal antibody therapy that has emerged as a promising treatment option for certain types of advanced skin cancer. Specifically designed to target the programmed cell death protein 1 (PD-1) pathway, cemiplimab works by blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby unleashing the body's immune system to recognize and attack cancer cells. We con … 